Eyam Health
Eyam Vaccines and Immunotherapeutics is a private Canadian company dedicated to the research and development of safe, efficacious, and low-dose vaccines. Named after the historic village in Derbyshire known for its selfless quarantine during the plague, the company aims to create sterilizing vaccines that halt infection and transmission of COVID-19 and its variants. Eyam is actively advancing preclinical and clinical trials, including efforts to develop pan-coronavirus vaccines capable of addressing current and future variants such as Omicron. The company leverages proprietary platforms like self-amplifying mRNA and collaborates with institutions like the University of British Columbia to innovate in vaccine technology. Eyam also focuses on next-generation vaccine technologies and has appointed new board members and scientific advisors to support its mission.
Industries
Nr. of Employees
small (1-50)
Eyam Health
Surrey, British Columbia, Canada, North America
Products
Computational antigen design platform
A bioinformatics platform combining machine learning and standardized genomics workflows to prioritize antigen and epitope targets for multi-antigen vaccine and immunotherapeutic design, with support for variant integration.
Self-amplifying nucleic-acid delivery platform
A vector architecture engineered to function as self-amplifying RNA or DNA, designed for large multi-epitope payloads, with formulation approaches to improve thermal stability and delivery options that may avoid lipid-nanoparticle dependency.
Computational antigen design platform
A bioinformatics platform combining machine learning and standardized genomics workflows to prioritize antigen and epitope targets for multi-antigen vaccine and immunotherapeutic design, with support for variant integration.
Self-amplifying nucleic-acid delivery platform
A vector architecture engineered to function as self-amplifying RNA or DNA, designed for large multi-epitope payloads, with formulation approaches to improve thermal stability and delivery options that may avoid lipid-nanoparticle dependency.
Services
Collaborative research, licensing and translational partnerships
Establishment and management of collaborative R&D projects and licensing agreements with academic and industry partners to advance platform vaccine and therapeutic candidates, including commercial licensing that can include manufacturing and distribution rights.
Preclinical development support
Design and execution support for preclinical study programs, including animal-model testing and integration with computational design outputs to evaluate candidate immunogenicity and efficacy.
Clinical development coordination
Coordination and program management services to support transition from preclinical studies into clinical trial activities and to manage clinical trial operations.
Collaborative research, licensing and translational partnerships
Establishment and management of collaborative R&D projects and licensing agreements with academic and industry partners to advance platform vaccine and therapeutic candidates, including commercial licensing that can include manufacturing and distribution rights.
Preclinical development support
Design and execution support for preclinical study programs, including animal-model testing and integration with computational design outputs to evaluate candidate immunogenicity and efficacy.
Clinical development coordination
Coordination and program management services to support transition from preclinical studies into clinical trial activities and to manage clinical trial operations.
Expertise Areas
- Vaccine platform research and development
- Computational antigen and epitope design
- Next-generation sequencing analysis and bioinformatics
- Self-amplifying nucleic-acid vaccine platforms
Key Technologies
- Self-amplifying nucleic-acid platforms (RNA/DNA)
- Next-generation sequencing (NGS) analysis pipelines
- Machine learning for antigen and epitope prediction
- High-performance computing for bioinformatics